Aytu BioPharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Aytu BioPharma (AYTU).

Price Target Range — 5 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingBuy# Analysts3Avg. Consensus PT$10Upside to Avg. PT+411.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 30, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$15→$15
Jun 11, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$14→$15
Dec 10, 2025	Ascendiant Capital	Edward Woo	PT Raise	Buy	$13→$13
Sep 25, 2025	Maxim Group	Naz Rahman	PT Cut	Buy	$9→$7
Sep 25, 2025	Ascendiant Capital	Edward Woo	PT Raise	Buy	$12→$13
Jul 1, 2025	Lake Street	Thomas Flaten	Initiate	Buy	$8
Jun 30, 2025	Ascendiant Capital	Edward Woo	Initiate	Buy	$12

Analyst Ratings News

Microsoft To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday

Analysts revised targets and ratings for KMX, ARX, JKHY, MRNA, GO, HNGE, AYTU and MSFT, with mixed upgrades, downgrades and reiterations.

Avi Kapoor

PRO
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $15

Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ:AYTU) with a Buy and raises the price target from $14.5 to $15.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $14.5

Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ:AYTU) with a Buy and raises the price target from $14 to $14.5.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $13

Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ:AYTU) with a Buy and raises the price target from $12.5 to $13.

Benzinga Newsdesk

PRO
Maxim Group Maintains Buy on Aytu BioPharma, Lowers Price Target to $7

Maxim Group analyst Naz Rahman maintains Aytu BioPharma (NASDAQ: AYTU) with a Buy and lowers the price target from $9 to $7.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $12.5

Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ: AYTU) with a Buy and raises the price target from $12 to $12.5.

Benzinga Newsdesk

Aytu BioPharma Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Aytu BioPharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Microsoft To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday

PRO
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $15

PRO
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $14.5

PRO
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $13

PRO
Maxim Group Maintains Buy on Aytu BioPharma, Lowers Price Target to $7

PRO
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $12.5

People Also Watch

People Also Watch

Aytu BioPharma Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Aytu BioPharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Microsoft To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday

PROAscendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $15

PROAscendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $14.5

PROAscendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $13

PROMaxim Group Maintains Buy on Aytu BioPharma, Lowers Price Target to $7

PROAscendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $12.5

People Also Watch

People Also Watch

PRO
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $15

PRO
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $14.5

PRO
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $13

PRO
Maxim Group Maintains Buy on Aytu BioPharma, Lowers Price Target to $7

PRO
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $12.5